Recorded on: September 8, 2023
1 CME Credit for physicians available until: September 27, 2024
1 NCPD Contact hour for nurses available until: September 27, 2024
1 CPE Contact hour for pharmacists available until: September 27, 2024
Format: Enduring Material
This activity is intended for hematologic oncology physicians, nurses, pharmacists, and advanced practice clinicians who provide care for individuals with hematologic malignancies, especially follicular lymphoma.
After completing this activity, the participant should be better able to:
- Apply prognostic tools to the evaluation and management of patients with FL, including patients with hallmarks of aggressive disease
- Compare and contrast mechanisms of action, efficacy data, and toxicity profiles for new and emerging therapies, including for third-line and later treatment settings in FL
- Select therapies for patients with RR FL in consideration of prior therapy, disease factors, patient factors, and treatment goals
Krish Patel, MD
Director, Lymphoma Program
Director, Hematologic Malignancies and Cellular Therapy
Center for Blood Disorders and Cellular Therapy
Swedish Cancer Institute
Adrienne Phillips, MD, MPH
Director, Cell Therapy and Bone Marrow Transplantation
Associate Professor of Medicine
Rutgers Robert Wood Johnson Medical School
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ
Tycel Phillips, MD
Associate Professor of Medicine
City of Hope
Continuing Education Information
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMA-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)TM into European CME credit (ECMEC®) should contact the UEMS (www.uems.eu).
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-23-083-H01-P
Type of Activity: Application
This activity is jointly provided by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
If you have questions regarding your certificate, please contact MLI at email@example.com.
For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: profeducation@LLS.org.